Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Big Pharma conclude M&A is not the new R&D.


Byline: Aarti Nagraj

Summary: World leaders For a list of heads of state, see .
World leaders is a MMORPG. The game involves creating a state, joining an alliance and going into war. It is mostly played by players from Israel, China, USA, Britain, Brazil and Saudi-Arabia.
 meet at the illustrious NGP NGP Neo-Geo Pocket (SNK)
NGP Nearest Grid Point
NGP New Growth Point (UK)
NGP National Grid Project
NGP Next-Generation Program (fire suppression)
NGP Next Generation Product
 Summit in Florida to face up to economic woes.

With large firms seeking synergies to drive down R&D costs, M&A deals can aid in the transfer of technical knowledge, scalability and reduce time to market. However, previous M&A periods have not alleviated the productivity crisis. While short term gains emerge from these deals, in the mid to long term, R&D innovation, organic growth, and internal drivers are still key facet's behind creating a successful company and providing an organization with sustainability.

a

The debate rages on at the NGP Summit (currently being held in Florida) where visionaries such as Jeffery Nye, Chief Medical Officer at Johnson & Johnson, Reinilde Heyrman--VP of Clinical aDevelopment at Daiichi Sankyo, Oscar Laskin--VP of Early Development at Celgene are leading the debate, joined by Ann Wang--VP of Clinical Operations at Human Genome Sciences Human Genome Sciences NASDAQ: HGSI is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs.  who have recently seen a surge of 277 % in their stock price owing to owing to
prep.
Because of; on account of: I couldn't attend, owing to illness.

owing to prepdebido a, por causa de 
 the continuing success of their 'Benlysta' drug.

a

The NGP Summit clearly illustrates that the pharmaceutical and biotechnology industry is in a state of transition. M&A, reorganization, consolidation, and portfolio changes are being evaluated in order to maintain growth centers in the face of a myriad of serious challenges. Companies such as Millipore, Definiens de·fin·i·ens  
n. pl. de·fin·i·en·ti·a
The word or words serving to define another word or expression, as in a dictionary entry.



[Latin d
 and PPD (1) (Parallel Presence Detect) The method used by earlier SIMM memory modules to communicate their capacity to the computer. A binary number coming from a parallel set of pins was read by the system, with each pin representing one bit. Contrast with SPD.  were called by the committee to share their thought leadership amongst over fifty of the worlds 'big Pharma' leaders.

a

"The willingness for the industry to unite in such a way clearly demonstrates long-term strategies for improved business processes so long-term investment in R&D can be secured". Drew Contessa -- NGP Director

a

Various economic pressures have triggered yet another wave in M&A deals in the industry as companies seek to bring in new assets, capabilities and infrastructures and redesign their organizations going forward. But is this sustainable for long-term growth? The fifty strong committee are set to rejoin re·join 1  
v. re·joined, re·join·ing, re·joins

v.tr.
To say in reply, especially in sharp response to a reply.

v.intr.
To reply.
 at the NGP in April 2010 to review.

@import url(http://www.kippreport.com/wp-content/themes/mimbo/rte);

2009 Dubai Business | Kippreport. All Rights Reserved.

Provided by Syndigate.info an Albawaba.com company
COPYRIGHT 2009 Al Bawaba (Middle East) Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Kippreport
Date:Oct 29, 2009
Words:356
Previous Article:Calling new numbers.
Next Article:Pirates demand $7 million ransom for British couple.
Topics:



Related Articles
Pharming licenses peptides.
Cleared Plaid AM hits back at 'smear.
Enterprising duo sell firm in pounds 20m deal.
Pfizer/Wyeth: indicative of poor health: Frost & Sullivan analyst A Shabeer Hussain, Programme Leader, Pharmaceutical and Biotechnology, Healthcare...
GVK Biosciences announces appointment of Gerhard N. Mayr to its Board of Directors.
Mergers and Acquisitions in the Pharma-Biotech Panorama

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles